SCHEMBL1015085

SCHEMBL1015085

Cc1ccc(-c2ccc3c(c2)CCN(CC(=O)N2CCN(C4CCC4)CC2)C3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KDM4E B2RXH2 3/20 0.47
PKM P14618 2/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 1/20 0.43
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HRH3 Q9Y5N1 2/20 0.40
KCNH2 Q12809 1/20 0.40
PARP1 P09874 1/20 0.39
KDM2B Q8NHM5 2/20 0.38
EGFR P00533 1/20 0.38
TYMS P04818 1/20 0.38
LTA4H P09960 1/20 0.38
VDR P11473 1/20 0.38
SRC P12931 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1018400 0.98 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1018217 0.97 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1020909 0.93 ALDH1A1 (0.42) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1017606 0.91 NPSR1 (0.45) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1017068 0.91 HTT (0.42) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1017491 0.91 HTT (0.44) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1016153 0.91 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1017111 0.90 MAPT (0.42) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1013944 0.90 HTT (0.43) ALDH1A1MEN1KMT2AKDM4EPKM
SCHEMBL1016580 0.90 HTT (0.43) ALDH1A1PKMNPSR1HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US claimed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ALDH1A1 1229/4885MEN1 2317/4885KMT2A 566/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ALDH1A1 1229/4885MEN1 2317/4885KMT2A 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.